15677-10-8

Basic information

• Product Name: 2,4-dimethyl-1,2,4-triazine-3,5-dione
• Synonyms: 2,4-dimethyl-1,2,4-triazine-3,5-dione
• CAS NO: 15677-10-8
• Molecular Formula: C5H7N3O2
• Molecular Weight: 141.13
• Mol File: 15677-10-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 189.6°Cat760mmHg
• Flash Point: 68.5°C
• Appearance: /
• Density: 1.36g/cm³
• Vapor Pressure: 0.564mmHg at 25°C
• Refractive Index: 1.598
• PKA: -1.76±0.20(Predicted)
• CAS DataBase Reference: 2,4-dimethyl-1,2,4-triazine-3,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dimethyl-1,2,4-triazine-3,5-dione(15677-10-8)
• EPA Substance Registry System: 2,4-dimethyl-1,2,4-triazine-3,5-dione(15677-10-8)

Safety Data

• Hazardous Substances Data: 15677-10-8(Hazardous Substances Data)

Usage

Chemical structure

A triazine derivative with two methyl groups attached to the 2 and 4 positions, and a 3,5-dione group.

Physical form

White crystalline solid

Use as reagent

In organic synthesis, particularly in the preparation of heterocyclic compounds.

Use as crosslinking agent

In rubber vulcanization.

Use as flame retardant

In some industrial applications.

Potential as herbicide

Has been studied for its ability to control weeds.

Pharmaceutical intermediate

Can be used as a precursor for the synthesis of pharmaceutical compounds.

Antimicrobial properties

Has been investigated for its ability to inhibit the growth of microorganisms.

Antifungal properties

Has been studied for its ability to inhibit the growth of fungi.

InChI:InChI=1/C5H7N3O2/c1-7-4(9)3-6-8(2)5(7)10/h3H,1-2H3

Upstream product

• 461-89-2 6-azauracil 
• 74-88-4 methyl iodide 

Downstream Products

• 15870-78-7 5-bromo-1,3-dimethyl-6-azauracil 
• 2278-11-7 8-Azacaffeine 
• 1632-30-0 2,4,6-trimethyl-2H-[1,2,3]triazolo[4,5-d]pyrimidine-5,7(4H,6H)-dione 
• 84174-95-8 (3aR,7aS,7bS)-3a,7b-Dichloro-2-(3,5-dichloro-phenyl)-4,6-dimethyl-dihydro-2,3b,4,6-tetraaza-cyclopenta[3,4]cyclobuta[1,2]benzene-1,3,5,7-tetraone 
• 84174-96-9 4-((3aR,7aS,7bS)-3a,7b-Dichloro-4,6-dimethyl-1,3,5,7-tetraoxo-octahydro-2,3b,4,6-tetraaza-cyclopenta[3,4]cyclobuta[1,2]benzen-2-yl)-benzoic acid ethyl ester 

Relevant articles and documents

Stereoselective fluorescence quenching in the electron transfer photooxidation of nucleobase-related azetidines by cyanoaromatics

Electron transfer involving nucleic acids and their derivatives is an important field in bioorganic chemistry, specifically in connection with its role in the photo-driven DNA damage and repair. Four-membered ring heterocyclic oxetanes and azetidines have been claimed to be the intermediates involved in the repair of DNA (6-4) photoproduct by photolyase. In this context, we examine here the redox properties of the two azetidine isomers obtained from photocycloaddition between 6-aza-1,3-dimethyluracil and cyclohexene. Steady-state and time-resolved fluorescence experiments using a series of photoreductants and photooxidants have been run to evaluate the efficiency of the electron transfer process. Analysis of the obtained quenching kinetics shows that the azetidine compounds can act as electron donors. Additionally, it appears that the cis isomer is more easily oxidized than its trans counterpart. This result is in agreement with electrochemical studies performed on both azetidine derivatives.

3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT1A ligands

A 3,5-dioxo-(2H,4H)-1,2,4-triazine compounds of formula I STR1 in which: R1 and R2, which are identical or different, represent hydrogen or C1 -C6 alkyl, n is 2 to 6, inclusive, A represents aryl piperazino II STR2 the Ar grouping representing phenyl, naphthyl, pyrimidyl, or pyridyl, unsubstituted or substituted by C1 -C3 alkyl, C1 -C3 alkoxy, hydroxy, trifluoromethyl, or halogen, or III benzodioxanyl-methyl-amino or pyridodioxanyl-methyl-amino STR3 in which R represents hydrogen or C1 -C3 alkyl and X represents a nitrogen or carbon atom, therapeutically-acceptable salts and enantiomers thereof, pharmaceutical compositions thereof, and method for treatment of diseases requiring a 5HT1A receptor agonist therewith.